TRAIL: A Sword for Killing Tumors
Keywords: (DED); (FADD); (RIP); (TRADD); (TRAF2); 5-FU treatment; AIDS; Alzheimer's diseases; Apoptosis; Bak; Bax; Bcl-2; DR4; DcR1; DcR2; Eu-myc; Excessive apoptosis; FUT 3; FUT 6; GALNT14; GALNT3; Huntington's disease; JUN N-terminal kinase; KILLER/DR5; Osteoprotegerin; TNF; TNF family; TNF receptor superfamily; TRAIL; TRAIL apoptotic pathway; TRAIL-induced apoptosis; TRAIL-sensitive tumors; Tumor necro-sis factor (TNF)-related apoptosis-inducing ligand (TRAIL); Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL); XIAP; anti-TRAIL receptor; biomarker; c-FLIP; cancer therapy; carcinogenesis; cardiac ischemia; caspase-dependent pathway; chemo or; death inducing signaling complex; deficient apoptosis; drug design; extracellular signal-regulated kinase; homotrimer; interferons; mDcR1; mDcR2; mitogen-activated protein kinases; nuclear factor-B; radiotherapy; resistant tumor; tissue homeostasis
Document Type: Research Article
Publication date: 2010-10-01
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.